Nivolumab Induced Seronegative Arthritis in a Patient With Refractory Hodgkin’s Lymphoma

Abstract

Nivolumab is known to be a type of immune checkpoint inhibitors (ICIs) that targets programmed cell death protein-1 (PD-1). It is commonly used in the treatment protocols of malignant melanoma, Hodgkin's lymphoma, renal cell, squamous and nonsquamous lung cancers. 1,2 ICIs may cause immune-related adverse events (IRAEs). In this article, we report a case diagnosed with seronegative arthritis after nivolumab therapy. ABSTRACTNivolumab is a monoclonal antibody against programmed cell death protein-1 which is assessed in the group of immune checkpoint inhibitors. It may lead to immune-related adverse events. In this article, we report a 38-year-old male patient diagnosed with seronegative arthritis after nivolumab therapy. This case supports that clinicians should be attentive for immune-related adverse events after use of immune checkpoint inhibitors.